Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

JP Morgan analysts believe Ogsiveo's broad label is an outri...

JP Morgan analysts believe Ogsiveo's broad label is an outright victory for SpringWorks. They see the drug's global blockbuster potential and notice the company's research into its applicability to certain ovarian tumors and multiple myeloma.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more
1
+0
1
Translate
Report
8270 Views
Comment
Sign in to post a comment